Reply - 03/03/22
Doi : 10.1016/j.jaci.2021.12.766
Alexandra F. Santos, MD, PhD a, b, c, d 
, Ethan Evans e, Colin O'Rourke, MS e, Henry T. Bahnson, MPH e, f, Gideon Lack, MBBS, FRCPCH a, b, c, d
, Ethan Evans e, Colin O'Rourke, MS e, Henry T. Bahnson, MPH e, f, Gideon Lack, MBBS, FRCPCH a, b, c, d a Department of Women and Children’s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom
b Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom
c Children’s Allergy Service, Guy’s and St. Thomas’ Hospital, London, United Kingdom
d Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
e Benaroya Research Institute, Seattle, Wash
f Immune Tolerance Network, Seattle, Wash
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: A. F. Santos reports grants and personal fees from the Medical Research Council (grants G0902018, MR/M008517/1, and MR/T032081/1); grants from the Food Allergy Research and Education (FARE), the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Asthma UK, and the National Institute for Health Research (NIHR) through the Biomedical Research Centre (BRC) award to Guy's and St. Thomas' NHS Foundation Trust; personal fees from Thermo Scientific, Nutricia, Infomed, Novartis, Allergy Therapeutics, and Buhlmann; and research support from Buhlmann and Thermo Scientific through a collaboration agreement with King's College London. H. T. Bahnson reports grants from the NIAID of the NIH (grant UM1AI109565) and consulting fees from DBV Technologies and MyOR. G. Lack reports grants from the NIAID of the NIH (grants NO1-AI-15416 and UM1AI109565), FARE, the NIHR through the BRC award to Guy's and St. Thomas' NHS Foundation Trust, the National Peanut Board, the UK Food Standards Agency, and the Davis Foundation, as well as personal fees from Novartis, Aravax, ALK-Abelló, DBV Technologies, and Mighty Mission Me. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 3
P. 1129-1131 - mars 2022 Retour au numéro
Article précédent
- Life-threatening anaphylaxis to peanut — impossible to predict?
- Paul J. Turner, Adnan Custovic
- Epithelial repair in asthma: Defect or exaggerated?
- Carl Persson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?